In June of 2023, Blue Matter’s London team hosted the second meeting of the UK Biotech Club, inviting C-suite leaders and directors from 15 biotech companies in the Cambridge biotech sector. These companies are developing diagnostics, vaccines, discovery platforms, small molecule therapeutics and biologics, covering all lifecycle stages from discovery through to commercialization. Attendees discussed challenges, opportunities, and best practices for achieving success in the UK biotech scene and beyond. Topics included determining vision and direction, relationship building, extending the runway, and strategies for go-to-market success. In this paper, we share insights from these discussions and draw out the key takeaways.
